EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Searching for Novel COVID19 Treatments: Towards Covalent TMPRSS2 Inhibitors

Marco Minneci, Barbara Farkaš, Adeyemi Rahman, Inga Nehlmeier, Amy Eichmann, Stefan Pöhlmann iD, Isabel Rozas iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70524 ↗

At a glance

Journal article in ChemMedChem, 2026. Written by Marco Minneci and 6 co-authors. Institution: School of Chemistry, TBSI, Trinity College Dublin, Dublin, Ireland. Major MEDLINE topics: Serine Endopeptidases, COVID-19 Drug Treatment, Antiviral Agents, SARS-CoV-2. 57 references. The full text is freely available (open access, CC BY 4.0). Funded by: Science Foundation Ireland/Enterprise Ireland/Industrial Development Agency COVID-19 Rapid Response Funding Call, Science Foundation Ireland.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

We present the design, synthesis and biophysical and biochemical evaluation of new guanidinium derivatives with potential as covalent inhibitors of Transmembrane Protease Serine 2 (TMPRSS2), aiming to find therapies against COVID‐19. TMPRSS2 is a key protease for SARS‐CoV‐2 entry into host cells, making it a promising drug target since blocking viral entry, viral replication is stopped. We have designed five families of guanidinium derivatives with different scaffolds that would allow establishing covalent interactions with the target. The proposed structures were optimised for better binding and drug‐like properties. Docking studies showed that some of the new compounds had improved binding scores over nafamostat. Physicochemical and ADME properties analysis indicated that most of the compounds exhibit favourable drug‐like properties except for a small number that showed poor solubility or absorption. Different synthetic pathways were designed and optimised for the preparation of the five families, and the 40 compounds obtained were fully characterised. Unfortunately, in cell‐based assays, none of the new compounds prepared effectively blocked SARS‐CoV‐2 entry, suggesting that further optimisation is needed. Overall, the work presented expands the chemical space for targeting TMPRSS2 and provides valuable insights for future antiviral drug development.

Subjects

MeSH terms (MEDLINE)

Serine EndopeptidasesCOVID-19 Drug TreatmentAntiviral AgentsSARS-CoV-2Serine Proteinase InhibitorsGuanidineHumansMolecular Docking SimulationStructure-Activity RelationshipDrug DesignVirus InternalizationGuanidines

Author keywords

SARS‐CoV‐2TMPRSS2covalent inhibitionguanidino derivativesmolecular modelling

Substances

Serine EndopeptidasesTMPRSS2 protein, humanAntiviral AgentsSerine Proteinase InhibitorsGuanidineGuanidines

Authors and institutions

  • School of Chemistry, TBSI, Trinity College Dublin, Dublin, Ireland.
  • Infection Biology Unit, German Primate Center - Leibniz Institute for Primate Research, Göttingen, Germany.

ORCID profiles: Stefan Pöhlmann, Isabel Rozas

Funding

  • Science Foundation Ireland/Enterprise Ireland/Industrial Development Agency COVID-19 Rapid Response Funding Call
  • Science Foundation Ireland

Cite

APA

Minneci, M., Farkaš, B., Rahman, A., Nehlmeier, I., Eichmann, A., Pöhlmann, S., & Rozas, I. (2026). Searching for Novel COVID19 Treatments: Towards Covalent TMPRSS2 Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.70524

Vancouver

Minneci M, Farkaš B, Rahman A, Nehlmeier I, Eichmann A, Pöhlmann S, et al. Searching for Novel COVID19 Treatments: Towards Covalent TMPRSS2 Inhibitors. ChemMedChem. 2026. doi:10.1002/cmdc.70524

BibTeX
@article{Minneci2026,
  author = {Minneci, Marco and Farkaš, Barbara and Rahman, Adeyemi and Nehlmeier, Inga and Eichmann, Amy and Pöhlmann, Stefan and Rozas, Isabel},
  title = {Searching for Novel COVID19 Treatments: Towards Covalent TMPRSS2 Inhibitors},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70524}
}
Start for free →